Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Gap Up – Still a Buy?

Shares of Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) gapped up before the market opened on Friday. The stock had previously closed at $9.81, but opened at $10.15. Shionogi & Co., Ltd. Unsponsored ADR shares last traded at $9.52, with a volume of 1,111 shares traded.

Analyst Upgrades and Downgrades

Separately, Zacks Research raised shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 15th. Three analysts have rated the stock with a Strong Buy rating. According to MarketBeat.com, the stock currently has a consensus rating of “Strong Buy”.

Check Out Our Latest Stock Analysis on SGIOY

Shionogi & Co., Ltd. Unsponsored ADR Stock Down 0.8%

The business has a fifty day simple moving average of $9.34 and a 200 day simple moving average of $9.64. The firm has a market cap of $16.54 billion, a price-to-earnings ratio of 10.80, a PEG ratio of 3.46 and a beta of 0.10. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.14 and a quick ratio of 1.00.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY – Get Free Report) last posted its earnings results on Thursday, October 29th. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.13 by ($0.05). Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 37.95% and a return on equity of 14.32%. The company had revenue of $1.18 billion for the quarter, compared to the consensus estimate of $1.11 billion. As a group, equities analysts forecast that Shionogi & Co., Ltd. Unsponsored ADR will post 0.83 EPS for the current fiscal year.

About Shionogi & Co., Ltd. Unsponsored ADR

(Get Free Report)

Shionogi & Co., Ltd. is a Japan-based pharmaceutical company that researches, develops, manufactures and markets prescription medicines. Founded in Osaka in 1878, it has grown from a pharmaceutical wholesaler into a research-focused drugmaker. The company has a particular focus on infectious diseases, including HIV, influenza and COVID-19, and also works in areas such as pain and central nervous system disorders. Its products include Xofluza, an influenza treatment, and ensitrelvir, an oral COVID-19 antiviral marketed in Japan as Xocova.

Further Reading

Receive News & Ratings for Shionogi & Co. Ltd. Unsponsored ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shionogi & Co. Ltd. Unsponsored ADR and related companies with MarketBeat.com's FREE daily email newsletter.